+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists



Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists



Plos One 11(12): E0164485



Risk scores for patients who are at high risk for major bleeding complications during treatment with vitamin K antagonists (VKAs) do not perform that well. BLEEDS was initiated to search for new biomarkers that predict bleeding in these patients. To describe the outline and objectives of BLEEDS and to examine whether the study population is generalizable to other VKA treated populations. A cohort was created consisting of all patients starting VKA treatment at three Dutch anticoagulation clinics between January-2012 and July-2014. We stored leftover plasma and DNA following analysis of the INR. Of 16,706 eligible patients, 16,570 (99%) were included in BLEEDS and plasma was stored from 13,779 patients (83%). Patients had a mean age of 70 years (SD 14), 8713 were male (53%). The most common VKA indications were atrial fibrillation (10,876 patients, 66%) and venous thrombosis (3920 patients, 24%). 326 Major bleeds occurred during 17,613 years of follow-up (incidence rate 1.85/100 person years, 95%CI 1.66-2.06). The risk for major bleeding was highest in the initial three months of VKA treatment and increased when the international normalized ratio increased. These results and characteristics are in concordance with results from other VKA treated populations. BLEEDS is generalizable to other VKA treated populations and will permit innovative and unbiased research of biomarkers that may predict major bleeding during VKA treatment.

(PDF emailed within 0-6 h: $19.90)

Accession: 058445284

Download citation: RISBibTeXText

PMID: 27935941

DOI: 10.1371/journal.pone.0164485


Related references

Increased risk of major bleeding after a minor bleed during treatment with vitamin K antagonists is determined by fixed common risk factors. Journal of Thrombosis and Haemostasis 14(5): 948-952, 2018

Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists. British Journal of Haematology 153(4): 508-514, 2011

Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis. Plos One 10(9): E0137444, 2016

Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding. Seminars in Hematology 51(2): 102-111, 2014

The analysis of bleeding risk-prediction scores should include all major bleeds. Journal of the American College of Cardiology 61(4): 481-482, 2013

Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists. Medicine 94(52): E2366, 2016

Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: a multicenter retrospective cohort study. Haematologica 100(8): E295-E298, 2016

Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thrombosis and Haemostasis 115(2): 424-432, 2016

Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation 132(13): 1252-1260, 2016

Clinical management and outcome of major bleeding in patients on treatment with vitamin K antagonists. European Journal of Internal Medicine 33: 47-54, 2017

Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding. Academic Emergency Medicine 23(2): 144-150, 2016

Risk factors associated with a thrombotic or bleeding event in patients treated with vitamin K antagonists. Journal des Maladies Vasculaires 39(4): 248-255, 2016

Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. Thrombosis Research 138: 1-6, 2016

French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thrombosis Research 126(3): E167-E174, 2010

Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX. Journal of Thrombosis and Haemostasis 2(7): 1104-1109, 2004